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Abstract
Summary This posthoc analysis of four trials studied the
efficacy of risedronate to reduce fragility fractures in
postmenopausal women with osteopenia (i.e., T-scores
between −1a n d−2.5). Risedronate reduced the fracture risk
by 73% (p=0.023) in this population of women with low
femoral neck bone mass and no prevalent vertebral fractures.
Introduction Low bone mass represents an increasing
health risk and burden. Half of fragility fractures occur in
osteopenic women underscoring the need for treatments
reducing fracture risk. This analysis reports the effect of
risedronate to reduce fragility fracture risk in osteopenic
women without prevalent vertebral fractures.
Methods Postmenopausal women with osteopenia, defined
as femoral neck T-score between −1 and −2.5 by DXA and
no prevalent vertebral fractures, were identified from four
controlled randomized trials (BMD Multinational, BMD
North America, VERT Multinational and VERT North
America). The risk reduction for fragility fractures in
patients receiving 5 mg risedronate daily for 1.5 to 3 years
compared to placebo was assessed. An additional sensi-
tivity analysis excluded patients who were osteopenic at the
femoral neck but had a BMD lower than −2.5 SD at the
lumbar spine.
Results Six hundred and twenty postmenopausal women
with osteopenia were included, receiving either placebo
(n=309) or risedronate 5 mg (n=311). Risedronate reduced
the risk of fragility fractures by 73% over 3 years versus
placebo (p=0.023); cumulative fragility fracture incidence
was 6.9% in placebo-treated versus 2.2% in risedronate-
treated patients. The magnitude of the effect was similar in
the sensitivity analysis subset.
Conclusion Risedronate significantly reduced the risk of
fragility fractures in postmenopausal women with osteope-
nia (femoral neck T-score between −1 and −2.5 SD) and no
prevalent vertebral fractures.
Keywords Bisphosphonates.Fragilityfracture.
Nonvertebralfracture.Osteopenia.Risedronate.
Vertebralfracture
Introduction
Low bone mass, defined by bone mineral density (BMD)
values in the osteopenic range, can progress to osteoporosis
if left untreated. Additionally, it has recently become
apparent that osteopenia is a significant risk factor for
fragility fractures in older women. Studies using peripheral
and central dual x-ray absorptiometry (DXA) to determine
BMD have demonstrated that approximately half of all
fragility fractures occur in women with osteopenic BMD
[1–5]. As the number of women with low bone mass is
projected to increase to 30.4 million in 2020, this condition
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burden [6]. Prevalence projections for 2020 are signifi-
cantly higher than current rates (21.8 million women in
2002) due to expected population growth and aging [7].
Based on BMD testing, the World Health Organization
(WHO) clinically defines women with osteopenia as those
whose BMDT-score isbetween 1 and2.5 standard deviations
(SD) below the mean of peak bone mass in healthy, young
normal women (i.e., −1t o−2.5 SD); women with osteopo-
rosis include all those at or below −2.5 SD [8–10]. However,
these definitions provide a diagnostic categorization of low
bone mass rather than an intervention threshold that could be
used to determine the need for the initiation of treatment to
reduce fracture risk. Physicians are often faced with making
treatment decisions for postmenopausal patients with T-
scores in the osteopenic range, increasing the need for
evidence-based guidance to define populations at high risk
for fracture [11].
The National Osteoporosis Foundation (NOF) currently
recommends an algorithm for initiation of therapy to reduce
the risk of fracture [12]. According to this algorithm,
treatment should be initiated in osteopenic women with T-
scores <−2.0 by central DXA with no risk factors and in
women with T-scores <−1.5 by central DXA with one or
more risk factors [9, 10, 12, 13].
Despite the existence of NOF guidelines for the
treatment of postmenopausal women with low bone mass,
limited clinical data exist as a foundation for supporting
therapeutic intervention in this group. Although it is
possible to identify osteopenic women at higher or lower
short-term risk for fracture [11], there are limited data
regarding the effectiveness of osteoporosis treatments to
lower fracture risk in these women. This is in part due to
the inherent difficulty in collecting fracture data from
osteoporosis trials, which usually exclude women with
higher T-scores who may fall into the osteopenic range. The
assembly of large data sets is, therefore, difficult and the
feasibility of prospective osteopenic fracture trials is limited
due the lower incidence of fracture in this population com-
pared with patients with osteoporosis [14]. The use of post
hoc analysis is one way to overcome some of these obsta-
cles and provide information about effectiveness of treat-
ments in non-osteoporotic populations.
We have analyzed data from four Phase III risedronate
trials: BMD Multinational (BMD-MN) [15], BMD-North
America (NA) [16], Vertebral Efficacy with Risedronate
Therapy-Multinational (VERT-MN) [17], and Vertebral
Efficacy with Risedronate Therapy-North America (VERT-
NA) [18] in which efficacy and safety of risedronate in the
prevention and treatment of postmenopausal osteoporosis
have been demonstrated. Using data only from osteopenic
women included in these trials, this study evaluated the
effect of risedronate in reducing the risk of fragility fractures
in women with femoral neck T-scores in the osteopenic
range and without prevalent vertebral fracture.
Methods
Study design and patients
This retrospective analysis included the subsets of post-
menopausal women with osteopenia in four risedronate
placebo-controlled osteoporosis trials [15–18] of 1.5 to 3
years’ duration.
Patients included in the current analysis were postmen-
opausal women who had no radiographic vertebral fractures
at baseline and had a femoral neck T-score between −1 and
−2.5 SD as measured by DXA (NHANES III). These
selection criteria were similar to those in previously
published studies looking at similar populations [19, 20].
Although inclusion criteria for the VERT trials required
patients to have prevalent vertebral fractures, re-adjudication
conducted by central radiographic assessment after enroll-
ment showed that between 10% and 15% of enrolled patients
had no prevalent vertebral fracture and could, therefore, be
included in the present study. Our analysis was based on
BMD assessment at the femoral neck rather than the lumbar
spine, due to its greater reliability and predictive value and
wideacceptanceinternationallyforclinicaldiagnosis[2, 13].
Patients treated with estrogen and estrogen-related drugs
within 3 months of study entry or for more than 1 month
within 6 months of study entry were excluded from the
original studies. All patients received 1,000 mg calcium
and, if needed, 500 IU vitamin D daily.
Adverse event information was collected at the study
visits made every 3monthsduringthetrials. The investigator
recorded adverse events reported by the patients, as well as
adverse events observed on examination of the patient.
Identification of fragility fractures
Fragility fractures were defined as a composite of a patient’s
incident morphometric vertebral and osteoporosis-related
nonvertebral fractures (i.e., six fracture types including
clavicle, humerus, wrist, pelvis, hip or leg fractures). This
endpoint was chosen to include all radiographically con-
firmed fractures.
With respect to the nonvertebral fractures, the selection of
the nonvertebral fracture sites (clavicle, humerus, wrist,
pelvis, hip or leg) followed the pre-specified definition of
osteoporosis-related nonvertebral fractures of the risedronate
trial program, which has been reported in all regulatory and
previousscientificreportsfromthisprogram.Allosteoporosis
related nonvertebral fractures required radiographic confir-
mation. The term “leg” fracture as used in the risedronate
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adverse event codes for fibula, tibia, subtrochanteric fracture,
and leg, but not those for ankle or distal tibia fracture, the
terms by which ankle fractures are usually reported.
Statistical analyses
The primary analysis focused on investigating the effect of
risedronate to reduce fragility fractures (both vertebral and
nonvertebral) in postmenopausal women who had no
radiographic vertebral fractures at baseline and were
considered osteopenic based on a femoral neck T-score
ranging between −1 SD and −2.5 SD.
For consistency with previous risedronate studies, the
statistical analysis used time-to-first-event methodology.
Cumulative fracture incidence was estimated using the
Kaplan–Meier method, and a Cox proportional hazards
regression model was used to estimate the relative fracture
risk reduction, via the hazard ratio (HR), between the
risedronate 5 mg and placebo groups. The regression model
was stratified for each trial to allow for separate underlying
hazard functions. In order to determine the acceptability of
combining data from all trials, potential heterogeneity
assessments were performed using the Cox regression
model to assess the trial-by-treatment, age-by-treatment
and baseline femoral neck BMD-by-treatment interactions.
Fracture efficacy for nonvertebral osteoporosis-related
fractures and new vertebral fractures were also investigated.
A sensitivity analysis was conducted to investigate whether
the exclusion of patients with lumbar spine T-score <−2.5
SD would influence the outcome of the primary analyses.
As the inclusion criteria for the primary analysis were low
bone mass at the femoral neck (BMD T-score between −1
and −2.5 SD), we felt it was important to test whether the
exclusion of patients with an osteoporotic BMD at another
site would significantly affect the results.
Adverse events, serious adverse events, withdrawals,
deaths, and upper gastrointestinal adverse events were
summarized by treatment group. Differences in the propor-
tions of patients between the treatment groups were tested
using the Fisher’s exact test.
Results
Patients
A total of 620 postmenopausal women met the criteria for
low bone mass and were included in the current analysis.
Patients received either placebo (n=309) or risedronate
5 mg (n=311). Baseline characteristics were similar for
each patient group (Table 1). The mean age was 64 years
for both groups and mean baseline femoral neck T-scores
were −1.84 in the placebo group and −1.85 in the
risedronate group, respectively.
Potential heterogeneity assessments revealed that there
were no significant interactions for trial-by-treatment (p=
0.495), age-by-treatment (p=0.981) or baseline femoral
neck BMD-by-treatment (p=0.188)
Effect on fractures
Risedronate treatment was found to significantly reduce the
risk of combined morphometric vertebral and nonvertebral
fractures by 73% in women with a femoral neck T-score
between −1 and −2.5 and no prevalent vertebral fracture;
HR=0.27, 95%CI=0.09–0.83, p=0.023 (Fig. 1). The
cumulative fragility fracture incidence was 6.9% and 2.2%
respectively for placebo and risedronate.
When separated according to nonvertebral and vertebral
fractures, thecumulative nonvertebral fracture incidence was
5.4% and 0.4%, respectively, for placebo and risedronate
(HR=0.09, 95%CI=0.01–0.71 (p=0.022), and the cumu-
lative vertebral fracture incidence was 4.2% and 1.8%,
respectively, for placebo and risedronate (HR=0.44, 95%
CI=0.11–1.78 (p=0.249).
All patients Excluding lumbar spine
T-score <−2.5 SD
Placebon
n=309
Risedronate
5m gn = 3 1 1
Placebon
n=146
Risedronate
5 mg n=147
Age (years)
a 64 (7.5) 64 (7.5) 63 (8.3) 65 (7.0)
Femoral neck T-score
a, b −1.84 (0.396) −1.85 (0.406) −1.77 (0.418) −1.76 (0.398)
Height (cm)
a 159.8 (6.92) 159.8 (6.05) 160.6 (6.14) 160.4 (6.32)
Weight (kg)
a 65.9 (11.92) 66.8 (11.19) 69.8 (12.91) 69.6 (12.27)
BMI (kg/m
2)
a 25.9 (4.54) 26.2 (4.36) 27.2 (5.1) 27.1 (4.78)
Patients with prevalent
OP-related nonvertebral fractures
56 (18%) 59 (19%) 34 (23%) 31 (21%)
Table 1 Baseline characteris-
tics of patients with a femoral
neck T-Score ≥− 2.5 SD and
≤− 1 SD without prevalent
vertebral fractures
a Mean (standard deviation)
b Based on National Health
and Nutrition Examination Sur-
vey III reference database
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WhenpatientswithbaselineLSspineT-scoresbelow−2.5SD
were excluded, results consistent with those from the primary
analysis population were observed, although the reduced
sample size widened the confidence intervals and led to a loss
of statistical significance. For the 293 patients who had both
femoral neck and LSspine T-scoresbetween −2.5 and −1S D ,
the hazard ratio for fragility fractures was 0.22 (95%
CI=0.03–2.02, p=0.182), a magnitude of effect similar to
that in the primary analysis population.
Safety
In the subgroup investigated for this analysis, no statisti-
cally significant differences in adverse events between the
risedronate treated and the placebo group were recorded
during the trial (Table 2). The observation in the subgroup
analysis reported here is consistent with the findings in the
overall population of the original trials [15–18].
Discussion
Osteopenia is common in postmenopausal women and
contributes to the increased risk of fracture in this
population. There is a need for clinical data examining
both fracture risk in women with T-scores in the osteopenic
range and the evidence for an effect of treatment on
reducing that risk. Data from the National Osteoporosis
Risk Assessment (NORA) study reported that more than
half of women experiencing self-reported fractures of the
hip, vertebrae, rib and wrist/forearm at one year fell into the
osteopenic category based on peripheral BMD T-scores
between −1 and −2.5 [21]. Results from the present study
show that risedronate treatment significantly reduced the
overall risk of fragility fractures by 73% over 3 years in
patients with a femoral neck T-score between −1 and −2.5
and no prevalent vertebral fracture. A similar reduction in
risk — that did not reach statistical significance due to low
numbers — was observed when patients with lumbar spine
T-scores below −2.5 were excluded from the analysis.
Previous studies in women with osteoporosis have shown
that risedronate reduces the risk of morphometric vertebral
fractures by up to 65% in the first year of treatment [17, 18],
with significant reductions in clinical vertebral and non-
vertebral fractures as early as 6 months [22, 23]. Moreover,
a study in osteoporotic women without prevalent fracture
demonstrated that treatment with risedronate reduced the
risk of first vertebral fracture by 75% (i.e., a relative risk
of 0.25) [24].
Previously reported studies have examined the efficacy
of alendronate [20, 25] and raloxifene [19] on fracture risk
reduction in osteopenic populations. A retrospective re-
analysis of data from the Fracture Intervention Trial (FIT)
showed a 60% reduction of vertebral fractures [RR 0.40
(0.19–0.76 95% CI)] in osteopenic women defined as
having a femoral neck BMD T-score between −1.6 and
−2.5 [20]. The overall analysis included patients with or
without prevalent vertebral fractures, however, and since
prevalent vertebral fractures are an important risk factor
for further fractures and a criterion for severe osteoporosis
[8, 13], classifying such women as osteopenic is subject to
debate. When a subset of this population, those without
Fig. 1 Reduction of fragility fracture risk in patients with femoral neck
T-score between −1a n d−2.5 SD and no prevalent vertebral fractures
Table 2 Summary of adverse
events (AEs) for patients with
a femoral neck T-score ≥− 2.5
SD and ≤− 1 SD and no
prevalent vertebral fractures
(BMD and VERT Trials)
p-values were from Fisher’s
exact test.
UGI: upper gastrointestinal
Category Number of patients (%) p-value
Placebo (n=309) Risedronate 5 mg (n=311)
AEs 290 (93.9%) 293 (94.2%) 0.87
Serious AEs 40 (12.9%) 56 (18.0%) 0.10
AEs associated with death 2 (0.6%) 0 (0.0%) 0.25
UGI AEs 77 (24.9%) 81 (26.0%) 0.78
Withdrawn due to AEs 38 (12.3%) 26 (8.4%) 0.11
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were similar, but did not reach statistical significance [RR
0.46 (0.16−1.17 95% CI)]. Results in patients with both hip
and spine BMD in the osteopenic range are not reported in
this paper. A re-analysis of the Multiple Outcomes of
Raloxifene Evaluation (MORE) study reported similar rates
of vertebral fracture risk reduction in raloxifene-treated
women with osteopenia – defined as a total hip T-score >
−2.5 without a prevalent vertebral fracture - compared with
those with osteoporosis at 3 years [19]. The relative risk
reduction for vertebral fractures with raloxifene compared
with placebo was 0.53 (0.32–0.88, 95% CI) in osteopenic
women; the relative risk for clinical vertebral fractures in
osteopenic women was 0.25 (0.04–0.63). Information about
reduction of nonvertebral fractures has not been provided in
either the alendronate or raloxifene analyses. Conjugated
equine estrogens significantly reduced the risk of clinical
vertebral, hip and total fractures in postmenopausal women
in the Women’s Health Initiative, the vast majority of whom
did not have bone density testing but who were not selected
based on having diagnosed osteoporosis [26]. Finally, a
study of women ≥75 years of age in the UK reported that
oral daily clodronate 800 mg for 3 years reduced any clinical
fracture by 20%, but not hip fractures, in women unselected
forhavingosteoporosis[27]. This reduction was independent
of baseline BMD, but the number needed to treat was greater
in the non-osteoporotic subjects.
The fracture benefit observed with risedronate in patients
withlowbonemassinour analysismayresultinpartfromthe
effect of this compound on the preservation of bone micro-
architecture.Inprevious studies ofbothearlypostmenopausal
women and osteoporotic patients risedronate was observed to
preserve trabecular architecture, including trabecular number,
thickness and separation, compared to placebo [28, 29],
which is likely to contribute to a maintenance of bone
strength [30]. This beneficial effect on trabecular architecture
has also been observed with long-term treatment with
risedronate, as shown by recent data from a study in post-
menopausal osteoporotic women [31]. Bone microarchitec-
ture, assessed by three-dimensional micro-computed
tomography, was maintained at similar levels over a five-
year treatment period [31]. The sustained preservation of
bone microarchitecture equates to a long-term beneficial
effect on bone strength and may contribute to the decrease in
fracture risk observed with risedronate treatment.
Limitations of the current study include the selection of
initial populations in the VERT and BMD trials based on
the presence of risk factors for osteoporosis (including low
BMD and prevalent vertebral fractures). Because the
original trials were designed to examine the efficacy of
osteoporosis treatments in an osteoporotic population,
rather than to determine representative incidence of fracture
in a general osteopenic population, the data provided in the
present analysis may reflect an overestimation of the
fracture risk in the general postmenopausal population.
It is likely that in the relatively near future fracture risk
assessment using a combination of femoral neck BMD, age,
and other risk fractures will be utilized to determine
absolute fracture risk and also serve as a basis for
determining treatment intervention thresholds. In many
older postmenopausal women, osteopenia will be an
important risk factor for fracture, placing some of them at
high absolute risk of a fracture event over a 10 year interval
[32], and treatment with a pharmacologic agent will be
indicated to lower risk. The data presented here demon-
strate that in addition to the established efficacy in
preventing fracture in osteoporotic women with or without
prevalent fractures, risedronate significantly reduces the
risk of fragility fractures in this population of postmeno-
pausal women with osteopenic BMD values at the femoral
neck and no prevalent vertebral fractures.
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